Healthcare New Lows: Dipexium Pharmaceuticals (NASDAQ:DPRX), Ignyta Inc (NASDAQ:RXDX), MELA Sciences (NASDAQ:MELA), Onconova Therapeutics (NASDAQ:ONTX)

Investment analysts at Oppenheimer began coverage on shares of Dipexium Pharmaceuticals (NASDAQ:DPRX) in a note issued to investors on Monday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $27.00 price target on the stock. Oppenheimer’s price target indicates a potential upside of 194.76% from the stock’s previous close. Dipexium Pharmaceuticals Inc (NASDAQ:DPRX), shares after opening at $9.85 moved to $9.85 on last trade day and at the end of the day closed at $9.16. Company price to cash ratio as 19.07. Dipexium Pharmaceuticals Inc (NASDAQ:DPRX), showed a negative weekly performance of 8.40%.

On April, 1, 2014, Ignyta Inc. (Nasdaq: RXDX) an oncology precision medicine biotechnology company announced that it has issued inducement awards to three new non-executive employees. Ignyta Inc (NASDAQ:RXDX), shares fell 7.97% in last trading session and ended the day on $7.39.

On Mar 17, 2014, MELA Sciences Inc (NASDAQ:MELA), developer of MelaFind , an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, announced financial results for the fourth quarter and year ended December 31, 2013. MELA Sciences Inc (NASDAQ:MELA), shares moved down 6.82% in last trading session and was closed at $0.560, while trading in range of $ 0.55 – 0.62. MELA Sciences Inc (NASDAQ:MELA), year to date (YTD) performance is -12.50%.

Onconova Therapeutics Inc (NASDAQ:ONTX), share price has entered into oversold territory with an RSI value of 19.3. The Zacks Consensus Estimate for Onconova for the full year period has improved 75 cents over the past two months to $-2.09 per share. Currently, Onconova has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get in on after its recent drop. Onconova Therapeutics Inc (NASDAQ:ONTX), weekly performance is -9.68%. On last trading day company shares ended up $5.69. Onconova Therapeutics Inc (NASDAQ:ONTX), distance from 50-day simple moving average (SMA50) is -43.12%. Analysts mean target Price for the company is $11.50.